I think FDA delay could be to buy some time for the Rendesivir to make money in the market. i am sure Remdesivir can servive till all other player get FDA approve , right now they all in clinical phase1/2/3.

One of the tough competitors for leronlimab is Regeneron's cocktail drug which has IL-6 reducer/ inhibitor